Biomarker-driven Celecoxib Treatment Does Not Improve Survival Outcomes in NSCLC

Share this content:
Biomarker-driven treatment of non–small cell lung cancer with celecoxib failed to improve outcomes.
Biomarker-driven treatment of non–small cell lung cancer with celecoxib failed to improve outcomes.

Biomarker-driven treatment of non–small cell lung cancer (NSCLC) with celecoxib failed to improve outcomes, according to a prospective study published in the Journal of Clinical Oncology.1

The purpose of this trial was to prospectively confirm findings from the CALGB 30203 trial (ClinicalTrials.gov Identifier: NCT00070486) in which celecoxib plus chemotherapy improved progression-free survival (PFS) and overall survival (OS) among patients with moderate to high COX-2 expression.

The double-blind, phase 3 CALGB 30801 trial (ClinicalTrials.gov Identifier: NCT01041781) planned to randomly assign 322 patients with a COX-2 index of at least 2 to receive standard chemotherapy plus 400 mg celecoxib twice daily or placebo.

At baseline, the median age was 64, 84.6% of patients were Caucasian, and 54% were male. Performance statuses were 0 (39.4%), 1 (52.2%), or 2 (8.3%) in the trial. COX-2 expression levels were among 28.2% and were at least 4 among the remaining patients.

Only 312 patients were enrolled due to study discontinuation for futility.

There was no difference in median PFS among patients with a COX-2 index of at least 2 but less than 4 (5.16 vs 5.26 months; hazard ratio [HR], 1.076; 95% CI, 0.853-1.367) or at least 4 (5.16 vs 5.45 months; HR, 1.046; 95% CI, 0.794-1.377) compared with placebo.

There was also no difference in median OS among patients with a COX-2 index of at least 2 and less than 4 (13.4 vs 13.8 months; P = .1816) or at least 4 (10.8 vs 6.1 months; P = .1909) compared with placebo.

Adding celecoxib to chemotherapy did not increase toxicity.

RELATED: FDA Approves Brigatinib for ALK+ NSCLC After Crizotinib

According to the authors, this was the first biomarker-driven trial in NSCLC conducted in the United states. The results, however, “failed to confirm that COX-2 inhibition in addition to standard chemotherapy treatment for patients who were selected by COX-2 expression could improve outcomes,” wrote the authors.

Reference

  1. Edelman MJ, Wang X, Hodgson L, et al. Phase III randomized, placebo-controlled, double-blind trial of celecoxib in addition to standard  chemotherapy for advanced non–small-cell lung cancer with cyclooxygenase-2 overexpression: CALGB 30801 (Alliance). J Clin Oncol. 2017 May 10. doi: 10.1200/JCO.2016.71.3743 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters